Atlas Molecular Pharma was founded in Biscay (Spain) in September 2015 as a spin-off company of the Centre for Co-operative Research in Biosciences (CIC bioGUNE).
Our business model is to discover first-in-class, innovative therapeutics for the treatment of Rare and Ultra-Rare Diseases and license them to larger partners who will deliver them to market for the patients that need them.
Patient’s with Rare and ultra-Rare diseases, and their families who care for and support them, face significant and numerous challenges in their daily lives. Our focus is to use our innovative approach and expertise to discover new treatments, which these patients not only need but also clearly deserve, in order to improve their quality of life.
Our approach is to tackle rare diseases using pharmacological chaperones. Atlas Molecular Pharma has a proprietary technological platform approach (Chassys™) that acts as a “drug discovery engine” to deliver therapeutics (termed pharmacological chaperones) for the treatment of a range of Rare and Ultra-Rare Diseases.
By designing and discovering pharmacological chaperones (drugs) which associate to these enzymes and stabilise them, we aim to resolve the corresponding pathology of the disease and to have a significant positive impact on patient’s lives.